The multitude of favorable effects of GLP-1 RAs have led to their increased use in other patient populations, including those with cardiometabolic disease but without T2DM (eg, prediabetes,18,19 hypertension,20 metabolic dysfunction-associated steatohepatitis21), cardiovascular disease,22, 23, 24 chronic kidney disease,25 and sleep apnea.26 This evidence concerns the gene GLP1R and Hypertension.